Home Resume Publications Gordi Family Foundation


Dr. Gordi's Publications



    Review Articles
    1. Drug discovery and development: Lessons from an undeveloped drug. Gordi T. Expert Rev Clin Pharmacol. 2012 Mar;5(2):157-612.
    2. Artemisinin derivatives: toxic for laboratory animals, safe for humans? Gordi T, Lepist EI. Toxicol Lett. 2004 March;147(2):99-107.


    Full Articles
    1. Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors. Sy SKB, Chia YL, Gordi T, Hoch U, Eldon MA. Cancer Chemother Pharmacol. 2018 Mar 21. doi: 10.1007/s00280-018-3562-3

    2. Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO-029 Antibody for Muscular Dystrophy. Singh P, Rong H, Gordi T, Bosley J, Bhattacharya I. Clin Transl Sci. 2016 Oct 4.

    3. Population pharmacokinetics of boosted-elvitegravir in HIV-infected patients. Custodio JM, Gordi T, Zhong L, Ling KH, Ramanathan S. Journal of Clinical Pharmacology. 2015 Oct 9.

    4. Pharmacokinetic analysis of 14C-ursodiol in newborn infants using accelerator mass spectrometry. Gordi T, Baille R, Vuong LT, Abidi S, Dueker S, Vasquez H, Pegis P, Hopper AO, Power GG, Blood AB. Journal of Clinical Pharmacology. 2014 Sep;54(9):1031-7.

    5. Steady State Pharmacokinetics of Gabapentin after Administration of a Novel Gastroretentive Extended-Release Formulation in Postmenopausal Women with Vasomotor Symptoms. Cowles, VE, Gordi T, Hou, E. Clinical Drug Investigation. 2012 Sep 1;32(9):593-601.

    6. Artemisinin derivatives with long elimination half-life. Gordi T. J Pharm Pharmacol. 2008 October;60(10):1277-8.

    7. Clinical development of metformin extended-release tablets for type 2 diabetes: an overview. Schwartz SL, Gordi T, Hou E, Cramer M, Heritier M, Cowles VE. Expert Opin Drug Metab Toxicol. 2008 September;4(9):1235-43.

    8. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. Gordi T, Hou E, Kasichayanula S, Berner B. Clin Ther. 2008 May;30(5):909-16.

    9. Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. Obua C, Hellgren U, Ntale M, Gustafsson LL, Ogwal-Okeng JW, Gordi T, Jerling M. Br J Clin Pharmacol. 2008 April;65(4):493-501. (Click here for a free copy of this article.)

    10. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, Belardinelli L, Kerensky RA. J Nucl Cardiol. 2007 July;14(4):514-20.

    11. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. Gordi T, Blackburn B, Lieu H. J Clin Pharmacol. 2007 July;47(7):825-33.

    12. Retrospective analysis of artemisinin pharmacokinetics: application of a semiphysiological autoinduction model. Asimus S, Gordi T. Br J Clin Pharmacol. 2007 June;63(6):758-62. (Click here for a free copy of this article.)

    13. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H. Clin Pharmacokinet. 2006 ;45(12):1201-12.

    14. Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin. Gordi T, Xie R, Jusko WJ. Br J Clin Pharmacol. 2005 December;60(6):594-604. (Click here for a free copy of this article.)

    15. CYP3A and P-glycoprotein activity induction with St. John's Wort in healthy volunteers from 6 ethnic populations. Xie R, Tan LH, Polasek EC, Hong C, Teillol-Foo M, Gordi T, Sharma A, Nickens DJ, Arakawa T, Knuth DW, Antal EJ. J Clin Pharmacol. 2005 March;45(3):352-6.

    16. A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Gordi T, Xie R, Huong NV, Huong DX, Karlsson MO, Ashton M. Br J Clin Pharmacol. 2005 February;59(2):189-98. (Click here for a free copy of this article.)

    17. Simple solution to a common statistical problem: interpreting multiple tests. Gordi T, Khamis H. Clin Ther. 2004 May;26(5):780-6.

    18. The pharmacokinetics of linezolid are not affected by concomitant intake of the antioxidant vitamins C and E. Gordi T, Tan LH, Hong C, Hopkins NJ, Francom SF, Slatter JG, Antal EJ. J Clin Pharmacol. 2003 October;43(10):1161-7.

    19. Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens. Gordi T, Huong DX, Hai TN, Nieu NT, Ashton M. Antimicrob Agents Chemother. 2002 April;46(4):1026-31. (Click here for a free copy of this article.)

    20. Use of saliva and capillary blood samples as substitutes for venous blood sampling in pharmacokinetic investigations of artemisinin. Gordi T, Hai TN, Hoai NM, Thyberg M, Ashton M. Eur J Clin Pharmacol. 2000 November;56(8):561-6.

    21. Direct analysis of artemisinin in plasma and saliva using coupled-column high-performance liquid chromatography with a restricted-access material pre-column. Gordi T, Nielsen E, Yu Z, Westerlund D, Ashton M. J Chromatogr B Biomed Sci Appl. 2000 May;742(1):155-62.

    22. Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses. Ashton M, Gordi T, Trinh NH, Nguyen VH, Nguyen DS, Nguyen TN, Dinh XH, Johansson M, Le DC. Biopharm Drug Dispos. 1998 May;19(4):245-50.

    23. Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Ashton M, Nguyen DS, Nguyen VH, Gordi T, Trinh NH, Dinh XH, Nguyen TN, Le DC. Clin Pharmacol Ther. 1998 April;63(4):482-93.

    24. In-vitro interaction of artemisinin with intact human erythrocytes, erythrocyte ghosts, haemoglobin and carbonic anhydrase. Bakhshi HB, Gordi T, Ashton M. J Pharm Pharmacol. 1997 February;49(2):223-6.

    Poster Presentations
    1. Population Pharmacokinetics of Sofosbuvir and Its Major Metabolite (GS-331007) in Healthy and HCV-Infected Adult Subjects. B Kirby, T Gordi, WT Symonds, BP Kearney, and A Mathias. American Association for the Study of Liver Diseases meeting, 2013

    2. Population Pharmacokinetics of Tenofovir in Adult Healthy Subjects and HIV-infected Patients. S Ramanathan, T Gordi, JM Custodio, B Kearney. IWCPHT, 2013

    3. Population Pharmacokinetics of Cobicistat in Adult Healthy Subjects and HIV-infected Patients. JM Custodio, T Gordi, B Kearney, S Ramanathan. IWCPHT, 2013

    4. Poster Presentation at American Conference on Pharmacometrics (2011)

    5. Poster presentation at American Society of Clinical Pharmacology and Therapeutics (ASCPT) meetings (2006, 2011)

    6. Poster presentation at the annual meeting of Controlled Release Society (2007)

    7. Poster presentation at the annual meeting of the Endocrine Society (2007)

    8. Poster presentations at AAPS annual meetings (1997-2001, 2004-2006)

    9. Two posters at the 7th International Conference of Nuclear Cardiology (2005), both elected for oral presentation.

    Oral Presentations
    1. Invited speaker at Target Meeting's 3rd World Drug Discovery Online Conference (October 2013)

    2. Invited speaker at AAPS Bay Area Discussion Group presentation (September 2013)

    3. Invited speaker at 4th World PKPD Summit, Frankfurt, Germany (2012)

    4. Invited speaker at 3rd Pharmacokinetics & Pharmacodynamics meeting, Philadelphia (2012)

    5. Invited speaker at 2nd Annual Pediatric Pharmacology Conference, Philadelphia (2012)

    6. Speaker at Rosa's Impact Webinar Series (2012)

    7. Invited speaker at the AAPS Bay Area Discussion Group (2009)

    8. Speaker at AAPS meetings for best poster recognition (2001, 2005)

    Back to top
Contact: Tel: (408)-480-7314; E-mail:tg@tgordi.com